News - Amgen, romosozumab

Filter

Current filters:

Amgenromosozumab

Popular Filters

Switch to anabolics driving osteoporosis market growth

11-03-2013

A major paradigm shift in late and mid-stage product development from anti-resorptive therapies to anabolic…

AmgenAnti-Arthritics/RheumaticsMarkets & MarketingPharmaceuticalromosozumabUCB

UCB and Amgen not to progress development of romosozumab for fracture healing

13-02-2013

Belgium's leading drugmaker UCB (Euronext Brussels: UCB) and its partner, US biotech giant Amgen (Nasdaq:…

AmgenAnti-Arthritics/RheumaticsBiotechnologyPharmaceuticalResearchromosozumabUCB

Back to top